HARVARD BIOSCIENCE INC (HBIO) Earnings History

HARVARD BIOSCIENCE INC - Q4 2025 EarningsBeat

Filed at: Feb 10, 2026, 7:30 AM EST|Read from source

EXECUTIVE SUMMARY

Harvard Bioscience announced preliminary Q4 2025 results, indicating performance in line with guidance and strong year-over-year adjusted EBITDA growth. The company also outlined a new long-term strategy focused on becoming a leader in translational science tools, expanding consumables revenue, and improving operational performance.

POSITIVE HIGHLIGHTS

  • •

    Preliminary Q4 revenue of $23.7 million exceeded the midpoint of guidance.

    positive
  • •

    Gross margin of 60% was at the high end of the guidance range, driven by improved product mix and prior cost reductions.

    positive
  • •

    Adjusted EBITDA grew 27% year-over-year to $3.8 million, attributed to cost reduction, expense management, and execution.

    positive
  • •

    Company expects year-over-year revenue growth and mid-to high-single-digit EBITDA growth in 2026.

    positive

CONCERNS & RISKS

  • •

    Revenue of $23.7 million represents a modest increase from the prior quarter's $20.6 million, but historical context shows a declining trend in Q2 2025 ($20.4M) and Q1 2025 ($21.8M) compared to the previous year.

    attention
  • •

    While adjusted EBITDA grew YoY, the absolute value of $3.8 million in Q4 2025 is only slightly higher than the $3.0 million reported in Q1 2025, suggesting potential volatility in profitability.

    attention
  • •

    The company is undergoing a strategic shift towards higher-margin consumables and software, indicating a potential transition period with execution risks.

    attention

FINANCIAL METRICS

Revenue
Quarterly
$23.70M
N/A
Net Income
Quarterly
N/A
N/A
EPS (Diluted)
Quarterly
N/A
N/A
Operating Income
Quarterly
N/A
N/A
EPS (Basic)
Quarterly
N/A
N/A

MARGIN ANALYSIS

Gross Margin
Current Quarter
60.0%
YoY Change
N/A

Margin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.

MANAGEMENT GUIDANCE

FY2026

revenue
"year over year revenue growth"
adjusted EBITDA
"mid-to high-single-digit EBITDA growth"

Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.

MANAGEMENT COMMENTARY

Pleased with fourth quarter performance and excited to share go-forward strategy.

— HARVARD BIOSCIENCE INC, Q4 2025 2025 Earnings Call

Stronger foundation provided by refinancing and strategic consolidation.

— HARVARD BIOSCIENCE INC, Q4 2025 2025 Earnings Call

Scaling business model by focusing priorities on evolving needs of life sciences industry.

— HARVARD BIOSCIENCE INC, Q4 2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.